Cargando…
Towards identification of true cancer biomarkers
BACKGROUND: Most of newly discovered cancer biomarkers fail in the clinic because they lack sensitivity and/or specificity. The current explosion in knowledge of the mutational spectrum of many cancer types, as a result of whole exome and whole genome sequencing, has revealed a wide spectrum of muta...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161831/ https://www.ncbi.nlm.nih.gov/pubmed/25220599 http://dx.doi.org/10.1186/s12916-014-0156-8 |
_version_ | 1782334601204596736 |
---|---|
author | Diamandis, Eleftherios P |
author_facet | Diamandis, Eleftherios P |
author_sort | Diamandis, Eleftherios P |
collection | PubMed |
description | BACKGROUND: Most of newly discovered cancer biomarkers fail in the clinic because they lack sensitivity and/or specificity. The current explosion in knowledge of the mutational spectrum of many cancer types, as a result of whole exome and whole genome sequencing, has revealed a wide spectrum of mutations that appear to be highly specific for various cancer types. DISCUSSION: Mass spectrometry (MS) has the ability to monitor tryptic peptides in complex biological mixtures with high sensitivity and specificity. It may be possible in the near future to combine the known spectrum of gene mutations revealed by genomics with the power of MS, in order to quantify mutant peptides that are highly specific for cancer, in a multiplex fashion. Such mutant peptides, quantified in the circulation and other fluids, may represent tumor markers that are suitable for detection and monitoring of cancer. SUMMARY: The power of genomic and proteomic technologies can be combined to identify highly specific analytes for biomarker applications. |
format | Online Article Text |
id | pubmed-4161831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41618312014-09-13 Towards identification of true cancer biomarkers Diamandis, Eleftherios P BMC Med Opinion BACKGROUND: Most of newly discovered cancer biomarkers fail in the clinic because they lack sensitivity and/or specificity. The current explosion in knowledge of the mutational spectrum of many cancer types, as a result of whole exome and whole genome sequencing, has revealed a wide spectrum of mutations that appear to be highly specific for various cancer types. DISCUSSION: Mass spectrometry (MS) has the ability to monitor tryptic peptides in complex biological mixtures with high sensitivity and specificity. It may be possible in the near future to combine the known spectrum of gene mutations revealed by genomics with the power of MS, in order to quantify mutant peptides that are highly specific for cancer, in a multiplex fashion. Such mutant peptides, quantified in the circulation and other fluids, may represent tumor markers that are suitable for detection and monitoring of cancer. SUMMARY: The power of genomic and proteomic technologies can be combined to identify highly specific analytes for biomarker applications. BioMed Central 2014-09-11 /pmc/articles/PMC4161831/ /pubmed/25220599 http://dx.doi.org/10.1186/s12916-014-0156-8 Text en © Diamandis; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Opinion Diamandis, Eleftherios P Towards identification of true cancer biomarkers |
title | Towards identification of true cancer biomarkers |
title_full | Towards identification of true cancer biomarkers |
title_fullStr | Towards identification of true cancer biomarkers |
title_full_unstemmed | Towards identification of true cancer biomarkers |
title_short | Towards identification of true cancer biomarkers |
title_sort | towards identification of true cancer biomarkers |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161831/ https://www.ncbi.nlm.nih.gov/pubmed/25220599 http://dx.doi.org/10.1186/s12916-014-0156-8 |
work_keys_str_mv | AT diamandiseleftheriosp towardsidentificationoftruecancerbiomarkers |